Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire E Wainwright

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 7, 2004
Vitamin A levels in patients with CF are influenced by the inflammatory responseRistan M Greer, Helen M Buntain, Peter J Lewindon, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-RevisedSarah Acaster, Clara Mukuria, Donna Rowen, et al.
Cells|January 22, 2024
Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic FibrosisAbdullah A Tarique, Neeraj Tuladhar, Dean Kelk, et al.
JAMA|July 14, 2011
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trialClaire E Wainwright, Suzanna Vidmar, David S Armstrong, et al.
The European Respiratory Journal|April 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for <i>F508del</i> and a minimal function mutation: Results from a 96-week open-label extension studyMarcus A Mall, Claire E Wainwright, Julian Legg, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 24, 2020
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutationJane C Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, et al.
Journal of Medical Microbiology|April 28, 2021
Rapid macrolide and amikacin resistance testing for <i>Mycobacterium abscessus</i> in people with cystic fibrosisAmanda Bordin, Sushil Pandey, Christopher Coulter, et al.
The Journal of Pediatrics|July 6, 2014
Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosisMarj Moodie, Anita Lal, Suzanna Vidmar, et al.
Journal of Medical Microbiology|February 16, 2013
High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platformMelanie W Syrmis, Ralf J Moser, Timothy J Kidd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 7, 2004
Vitamin A levels in patients with CF are influenced by the inflammatory responseRistan M Greer, Helen M Buntain, Peter J Lewindon, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 12, 2022
Development of the Cystic Fibrosis Questionnaire-Revised-8 Dimensions: Estimating Utilities From the Cystic Fibrosis Questionnaire-RevisedSarah Acaster, Clara Mukuria, Donna Rowen, et al.
Cells|January 22, 2024
Azithromycin Augments Bacterial Uptake and Anti-Inflammatory Macrophage Polarization in Cystic FibrosisAbdullah A Tarique, Neeraj Tuladhar, Dean Kelk, et al.
JAMA|July 14, 2011
Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trialClaire E Wainwright, Suzanna Vidmar, David S Armstrong, et al.
The European Respiratory Journal|April 10, 2025
Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for <i>F508del</i> and a minimal function mutation: Results from a 96-week open-label extension studyMarcus A Mall, Claire E Wainwright, Julian Legg, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 24, 2020
A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutationJane C Davies, Isabelle Sermet-Gaudelus, Lutz Naehrlich, et al.
Journal of Medical Microbiology|April 28, 2021
Rapid macrolide and amikacin resistance testing for <i>Mycobacterium abscessus</i> in people with cystic fibrosisAmanda Bordin, Sushil Pandey, Christopher Coulter, et al.
The Journal of Pediatrics|July 6, 2014
Costs of bronchoalveolar lavage-directed therapy in the first 5 years of life for children with cystic fibrosisMarj Moodie, Anita Lal, Suzanna Vidmar, et al.
Journal of Medical Microbiology|February 16, 2013
High-throughput single-nucleotide polymorphism-based typing of shared Pseudomonas aeruginosa strains in cystic fibrosis patients using the Sequenom iPLEX platformMelanie W Syrmis, Ralf J Moser, Timothy J Kidd, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
Pageof 10